Insider Selling: Audentes Therapeutics Inc (BOLD) CEO Sells 700 Shares of Stock

Audentes Therapeutics Inc (NASDAQ:BOLD) CEO Matthew R. Patterson sold 700 shares of the stock in a transaction that occurred on Monday, April 2nd. The shares were sold at an average price of $30.01, for a total transaction of $21,007.00. Following the transaction, the chief executive officer now owns 700 shares in the company, valued at $21,007. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Shares of BOLD opened at $28.94 on Friday. The company has a market capitalization of $1,086.29, a price-to-earnings ratio of -8.51 and a beta of 1.39. Audentes Therapeutics Inc has a twelve month low of $13.90 and a twelve month high of $41.80.

How to Become a New Pot Stock Millionaire

Audentes Therapeutics (NASDAQ:BOLD) last announced its earnings results on Thursday, March 8th. The biotechnology company reported ($0.82) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.91) by $0.09. equities research analysts anticipate that Audentes Therapeutics Inc will post -3.43 EPS for the current year.

A number of equities analysts have recently issued reports on BOLD shares. BidaskClub upgraded shares of Audentes Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, December 20th. HC Wainwright started coverage on shares of Audentes Therapeutics in a research note on Wednesday, December 20th. They set a “buy” rating and a $37.00 price objective on the stock. Wedbush increased their price objective on shares of Audentes Therapeutics to $56.00 and gave the company an “outperform” rating in a research note on Thursday, January 4th. William Blair reiterated a “buy” rating on shares of Audentes Therapeutics in a research note on Friday, January 5th. Finally, BMO Capital Markets set a $44.00 target price on shares of Audentes Therapeutics and gave the company a “buy” rating in a research note on Friday, January 5th. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $35.56.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. boosted its stake in Audentes Therapeutics by 13.2% in the fourth quarter. BlackRock Inc. now owns 1,358,498 shares of the biotechnology company’s stock valued at $42,452,000 after acquiring an additional 158,576 shares in the last quarter. Jennison Associates LLC raised its holdings in shares of Audentes Therapeutics by 1.2% in the fourth quarter. Jennison Associates LLC now owns 853,822 shares of the biotechnology company’s stock worth $26,682,000 after buying an additional 9,762 shares during the last quarter. Perceptive Advisors LLC raised its holdings in shares of Audentes Therapeutics by 10.4% in the third quarter. Perceptive Advisors LLC now owns 781,309 shares of the biotechnology company’s stock worth $21,885,000 after buying an additional 73,809 shares during the last quarter. Citadel Advisors LLC raised its holdings in shares of Audentes Therapeutics by 206.2% in the fourth quarter. Citadel Advisors LLC now owns 339,588 shares of the biotechnology company’s stock worth $10,612,000 after buying an additional 228,667 shares during the last quarter. Finally, Farallon Capital Management LLC purchased a new position in shares of Audentes Therapeutics in the fourth quarter worth $9,989,000. Institutional investors own 66.96% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3334808/insider-selling-audentes-therapeutics-inc-bold-ceo-sells-700-shares-of-stock.html.

About Audentes Therapeutics

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Insider Buying and Selling by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

H&R REIT  PT Raised to C$24.50
H&R REIT PT Raised to C$24.50
Tamarack-Valley-Energy  Price Target Increased to C$4.00 by Analysts at Raymond James
Tamarack-Valley-Energy Price Target Increased to C$4.00 by Analysts at Raymond James
Assicurazioni Generali  Given a €15.90 Price Target at Citigroup
Assicurazioni Generali Given a €15.90 Price Target at Citigroup
PrairieSky Royalty  Stock Rating Lowered by TD Securities
PrairieSky Royalty Stock Rating Lowered by TD Securities
Methanex  Given a $69.50 Price Target by Scotiabank Analysts
Methanex Given a $69.50 Price Target by Scotiabank Analysts
Exelon  – Research Analysts’ Recent Ratings Updates
Exelon – Research Analysts’ Recent Ratings Updates


© 2006-2018 Ticker Report. Google+.